Seven in ten biologic-eligible severe asthma patients settled without a biologic

Design

Nationwide retrospective cohort with longitudinal trajectory clustering

Population

10,078 biologic-naive UK adults with severe asthma meeting biologic eligibility

Primary outcome

Exacerbation trajectory after first meeting eligibility

Effect

70% remitting-stable; 20% chronic-frequent; 10% refractory-frequent

Using nationwide UK primary care records, researchers identified 10,078 biologic-naive adults with severe asthma in the first year they had three or more steroid-treated exacerbations, the usual threshold for biologic eligibility, and tracked what happened next.

Three trajectories emerged. Seventy per cent were remitting-stable, falling to fewer than three exacerbations a year without a biologic even as inhaled steroid doses fell. Twenty per cent were chronic-frequent, with a median of five exacerbations a year, and 10% refractory-frequent, with a median of more than ten steroid courses a year. Chronic-frequent patients had higher blood eosinophils (median 0.30 vs 0.23 ×10⁹/L), visible several years before they became eligible. Remitting patients were least likely to have bronchiectasis.

Two lessons follow. First, a peak year of exacerbations often regresses, so improvement after starting a biologic is not all drug effect. Second, persistent eosinophilia identifies the patients most likely to keep exacerbating.

This does not argue against biologics for eligible patients, and guidelines are unchanged. It argues for careful selection, optimisation of standard care and honest assessment of response, which matters where biologics are costly, as in India.

• Expect many patients to improve after a peak exacerbation year, with or without a biologic
• Use persistently raised blood eosinophils to identify those likely to keep exacerbating
• Optimise inhaled therapy, adherence and comorbidities alongside biologic assessment
• Judge biologic response against the expected natural improvement, not the peak year
• Follow current guideline criteria for biologic eligibility; this study does not change them

Why it matters

It challenges the assumption that improvement after starting a biologic is all down to the drug.

Don't overread it

This observational study does not show that biologics are unnecessary for eligible patients.

The statistics, in plain English

Trajectories were identified by clustering, so the 70/20/10 split describes patterns in this population rather than fixed categories. Because patients entered at a peak, some improvement is expected statistically, a phenomenon called regression to the mean.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.